Skip to main content
Premium Trial:

Request an Annual Quote

Analyst: Illumina's Takeover Clock Ticking

One year. That's how long Illumina CEO Jay Flatley has to prove he can increase his company's value beyond Roche's $6.7 billion takeover bid, Maxim Group analyst Bryan Brokmeier tells Bloomberg.

As our sister publication GenomeWeb Daily News reports, Roche this week said it would not extend its $51-per-share cash tender offer, ending its bid for the firm for now. GWDN adds that Illumina's shareholders this week voted on four Illumina board member slots "as well as a move by Roche to amend Illumina's bylaws in order to expand the San Diego company's board." Illumina said its shareholders re-elected board members including Flatley, Chairman William Rastetter, Blaine Bowman, and Karin Eastham.

Maxim Group's Brokmeier tells Bloomberg that to make it tougher for Roche to gain control of his firm's board at its 2013 shareholder meeting, Flatley "must introduce new products, either in-house or through acquisitions, and expand sales to get the shares rising."

Brokmeier goes on to add that Roche's recent move — to let its tender offer expire — does not signal the end of its bid. "They may come back with an offer if Illumina shares don't move higher and shareholders see they shouldn't have walked. Or if Illumina comes out with better news on its pipeline and greater information," he tells Bloomberg.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.